भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Hologic makes medical devices and diagnostic tests focused on women's health. It builds the mammography and biopsy systems many hospitals use for breast-cancer screening, the molecular and cytology lab equipment that runs tests for infections and cervical cancer, surgical devices used in gynecological procedures such as fibroid removal, and bone-density scanners. Most of its products are sold to hospitals, imaging centers and diagnostic labs, either directly or through distributors and group purchasing contracts.
यह पैसा कैसे कमाती है
Revenue mixes one-time capital equipment sales, such as a mammography or bone-density system, with recurring, higher-margin consumables that the equipment's installed base keeps buying: diagnostic assay cartridges, biopsy needles and single-use surgical instruments. In the US, large hospital groups buy through group purchasing organizations that negotiate on behalf of most hospitals, which caps how much pricing power any single product can hold even where the equipment locks a customer in.
सेगमेंट के अनुसार राजस्व
Molecular and cytology tests run on Hologic's lab instruments, covering infectious disease and cervical-cancer screening.
Mammography and breast-biopsy systems, the segment's largest source of capital-equipment revenue.
Devices for gynecological surgical procedures plus bone-density scanners, the two smallest of Hologic's business lines.
प्रतिस्पर्धी बढ़त (Moat)
स्विचिंग कॉस्ट · संकीर्णA hospital that installs Hologic's Panther molecular-testing platform or its mammography systems keeps buying Hologic's matched consumables and service contracts for the equipment's life, since switching means requalifying a new system with clinicians and regulators. The advantage is narrow because Roche, BD and Siemens Healthineers sell comparable platforms and actively compete for the same equipment placements.
मांग को क्या चलाता है
डिफेंसिवCancer screening, infectious-disease testing and gynecological procedures follow clinical guidelines and reimbursement coverage rather than discretionary spending, which makes underlying demand fairly steady. The more cyclical piece is capital equipment: hospitals can defer replacing a mammography system in a tight budget year even while the tests it enables keep being ordered.
प्रमुख जोखिम
- Reimbursement and healthcare policy risk — Sales depend on government healthcare programs and private insurers continuing to cover and reimburse Hologic's tests and procedures at workable rates; adverse coverage or guideline changes reduce market acceptance.
- Group purchasing organization pricing pressure — Group purchasing organizations negotiate on behalf of most US hospitals and can push for steep discounts, limiting how much Hologic can charge even for products with a loyal installed base.
- Concentration in two business lines — Diagnostics and Breast Health together make up roughly four-fifths of revenue, so a setback in either, such as falling COVID-era test demand, affects the company disproportionately.
- Competition from larger, diversified rivals — Hologic competes against larger, more diversified medical-technology and diagnostics companies that can outspend it on research and undercut on price in individual product categories.
खरीदने के पक्ष में तर्क
Buyers argue that women's-health screening and testing volumes are structurally growing as guidelines expand, that the installed base of mammography and molecular-diagnostics equipment keeps generating high-margin consumable sales for years, and that fiscal 2025 growth in Breast Health and GYN Surgical shows the non-COVID business is healthy on its own.
बेचने के पक्ष में तर्क
Sellers worry that group purchasing organizations will keep compressing per-unit pricing, that Diagnostics revenue has yet to fully offset the loss of pandemic-era test volumes, and that a portfolio this concentrated in two business lines is vulnerable to a single reimbursement or competitive setback in either one.
Written by the editors, published on 18 अगस्त 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
सीमित वित्तीय डेटा उपलब्ध है (0% मेट्रिक्स)। स्कोर इस कंपनी के fundamentals को सटीक रूप से प्रतिबिंबित नहीं कर सकते।
बैलेंस शीट और तरलता
राजस्व
-
शुद्ध आय
-
Free Cash Flow
-
कुल इक्विटी
-
कुल देनदारियाँ
-
Current Ratio
3.75
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$31.68
वर्तमान मूल्य
-
Margin of Safety
-
Fair Value सीमा
$30.09 - $33.26
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
31.20
ROE
11.0%
P/B Ratio
-
P/FCF
-
Gross Margin
-
ROIC
-
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-
WACC
8.0%
ROIC − WACC
-
Fundamental विश्लेषण मानदंड
पास (0)
फेल (0)
अनुपलब्ध (1)
- Error fetching data
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for HOLX, sourced from Markets Gazette.
- 4/8/2026POSITIVEHologic Goes Private In $18 Billion Blackstone, TPG Acquisition
Blackstone and TPG have successfully completed their acquisition of Hologic Inc., taking the medical technology company private in a deal valued at up to $18 billion, or $79 per share. This transaction marks a significant shift for Hologic, moving it from public trading to private ownership under the stewardship of its new private equity owners. Investors who held Hologic stock prior to the acquisition will receive the specified cash consideration, realizing a return on their investment.
via Markets Gazette